Abstract
Thromboembolic disorders are a major cause of morbidity and mortality in industrialized countries. For prophylaxis of thrombosis at present the so-called indirect anticoagulants of the dicoumarol type, the biopolymer heparin and several antiplatelet drugs are used. The active principle of the medicinal leech, hirudin, is available now as a recombinant product and is being tested clinically. Each of the mentioned anticoagulants has its values and limitations, based either on the chemical nature or on the mode of action. Antithrombotic regimes that do not interfere with the coagulation system are proposed; their value, however, has not yet been fully documented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
T.A. Krenitsky, and G.B. Elion, Enzymes as tools and targets in drug research, in: Strategy in Drug Research, Ed.: J.A. Keverling Buisman, Elsevier, Amsterdam, 65 (1982).
T.M. Penning, Design of suicide substrates: an approach to the development of highly selective enzyme inhibitors as drugs, Trends Pharmacol. Sci. 4: 212 (1963).
H.J. Smith, Perspectives in the design of small molecule enzyme inhibitors as useful drugs, J. Theor. Biol. 73: 531 (1978).
C.T. Walsh, Suicide substrates, mechanism-based enzyme inactivators: recent developments, Ann. Rev. Biochem. 53: 493 (1984).
J.D. Geratz, and R.R. Tidwell, Current concepts of action of synthetic thrombin inhibitors, Haemostasis 7: 170 (1987).
F. Markwardt, Pharmacological control of blood coagulation by synthetic, low-molecular weight inhibitors of clotting enzymes. A new concept of anticoagulants, Trends Pharmacol. Sci. 1: 153 (1980).
F. Markwardt, G. Nowak, and J. Hoffmann, Comparative study of thrombin inhibitors in experimental microthrombosis, Thrombos. Haemostas. 49: 235 (1983).
E. Shaw, Synthetic irreversible inhibitors of coagulation enzymes, Folia Haematol. (Lpz.) 109: 33 (1982).
J. Stürzebecher, Inhibitors of thrombin, in: The Thrombin. Vol. I ed: R. Machovich, CRC Press, Boca Baton, Fl., 131 (1984).
J. Stürzebecher, and F. Markwardt, Synthetische Inhibitoren des Thrombins and andere Gerinnungsenzyme - Struktur and Wirkung, Beitr. Wirkst. Forsch. 16: 1 (1983).
D. Bagdy, E. Barabas, L. Sebestyen, M. Dioszegi, S. Fittler, S. Bajusz, and E. Szell, Correlation between the anticoagulant and antiplatelet effect of D-PhePro-Arg-H (RGH-2958), Thrombos. Haemostas. 58: 177 (Abstr. 649) (1987).
D. Bagdy, E. Barabas, E. Sze11, and S. Bajusz, Uber die biochemische Pharmakologie einger Tripeptidaldehyde, Folia Haematol. (Lpz). 109: 22 (1982).
E. Barabas, S. Bajusz, D. Bagdy, and E. Szell, Studies on the inhibition by synthetic tripeptides of blood clotting, Acta Biochim. Biophys. 11: 207 (1976).
J.I. Witting, C. Pouliott, J.L. C.talfamo, J. Fareed, and J.W. Fenton II, Thrombin inhibition with dipeptidyl argininals. Thromb. Res. 50: 461 (1986).
S. Bajusz, E. Szell, D. Bagdy, E. Barabas, G. Horvath, M. Dioszegi, S. Fittler, G. Szabo, A. Juhasz, E. Tomori, and G. Szilagy G, Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H, J. Med. Chem. 33: 1729 (1990).
S. Bajusz, The story of D-MePhe-Pro-Arg-H, the likely anticoagulant and antithrombotic of the future, Biokemie (Budapest) XIV /3: 127 (1990).
C. Kettner, and E. Shaw, D-Phe-Pro-ArgCH2C1 - A selective affinity label for thrombin. Thromb. Res. 14: 969 (1979).
H.R. Lijnen, M. Uytterhoeven, and D. Collen, Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones, Thromb. Res. 34: 431 (1994).
Bagdy, E. Barabas, M. Dioszegi, S. Bajusz, and A. Feher, Comparative studies on the anticoagulant effects of D-Phe-Pro-Arg-H /1/ and D-Phe-Pro-ArgCH2C1 /2/, Thrombos. Haemostas. 50: 53 (Abstr. 0146) (1983).
D. Collen, O. Matsuo, J.M. Stassen, C. Kenner, and E. Shaw, In vivo studies of a synthetic inhibitor of thrombin, J. Lab. Clin. Med. 99: 76 (1982).
J. Hauptmann, and F. Markwardt, Studies on the anticoagulant and anti-thrombotic action of an irreversible thrombin inhibitor, Thromb. Res. 20: 347 (1980).
W. Stuber, H. Kosina, and N. Heimburger, Synthesis of a tripeptide with a C-terminal nitrile moiety and the inhibition of proteinases, Int. J. Peptide Protein Res. 31: 63 (1988).
C. Kenner, L. Mersinger, and R. Knabb, The selective inhibition of thrombin by peptides of boroarginine, J. Biol. Chem. 265: 18289 (1990).
T. Ueda, C.M. Kam, and J.C. Powers, The synthesis of arginyl-fluoroalkanes, their inhibition of trypsin and blood-coagulation serine proteinases and their anticoagulant activity, Biochem. J. 285: 539 (1990).
R. Kikumoto, Y. Tamao, K. Ohkubo, T. Tezuka, S. Tonomura, S. Okamoto and H. Hijikata, Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of Na substituted L-arginine, J. Med. Chem. 23: 1293 (1980).
R. Kikumoto, Y. Tamao, T. Tezuka, S. Tonomura, H. Hara, K. Ninomiya, A. Hijikata, and S. Okamoto, Selective inhibition of thrombin by (2R,4R)-4-methyl1-(N2-((3-methyl-1,2,3,4-tetrahy-8. Quinolinyl)sulfonyl)-L-arginyl)-2piperidinecarboxylic acid, Biochemistry 23: 85 (1984).
S. Okamoto, A. Hijikata, R. Kikumoto, S. Tonomura, N. Hara, K. Ninomiya, Maruyama, S. Sugano, and Y. Tamao, Potent inhibition of thrombin by the newly synthesized arginine derivative No.805: the importance of the stereostructure of its hydrophobic carboxamide portion, Biochem. Biophys. Res. Commun. 101: 440 (1981).
S. Tonomura, R. Kikumoto, Y. Tamao, K. Ohkubo, S. Okamoto, A. Kinjo, A. Hijikata, A novel series of synthetic thrombin inhibitors. II. Relationships between structure of modified OM inhibitors and thrombin-inhibitory effect, Kobe J. Med. Sci. 26: 1 (1980).
J. Hauptmann, and F. Markwardt F, Pharmakologie synthetischer ThrombinInhibitoren. Beitr. Wirkst. Forsch. 26: 1 (1986).
F. Markwardt, and J. Hauptmann, Synthetische Thrombininhibitoren als Antithrombotika. Z. Klin. Med. 41: 540 (1986).
F. Markwardt, and J. Stürzebecher, Inhibitors of trypsin and trypsin-like enzymes with a physiological role, in: M.H. Sandler, J. Smith (eds.) Design of Enzyme Inhibitors as Drugs, Oxford University Press, Oxford, 619 (1989).
F. Markwardt, G. Wagner, J. Stürzebecher, and P. Walsmann, Na arylsulfonylw(4-amidinophenyl)-a-aminoalkyl-carboxlic amides - novel selective inhibitors of thrombin, Thromb. Res. 17: 425 (1980).
J. Hauptmann, Pharmacology of benzamidine-type thrombin inhibitors, Folia Haematol. (Lpz.) 109: 89 (1982).
J. Hauptmann, B. Kaiser, F. Markwardt, and G. Nowak, Anticoagulant and anti-thrombotic action of novel specific inhibitors of thrombin, Thrombos. Haemostas. 43: 118 (1980).
J. Stürzebecher, F. Markwardt, B. Voigt, G. Wagner, and P. Walsmann, Cyclic amides of Na-arylsulfonaminoacylated 4-amidinophenyl-alanine - tight binding inhibitors of thrombin, Thromb. Res. 29: 635 (1983).
Y. Cadroy, C. Caranobe, A. Bernat, J.P. Maffrand, P. Sie, and B. Boneu, Antithrombotic and bleeding effects of a new synthetic thrombin inhibitor and of standard heparin in the rabbit, Thrombos. Haemostas. 58: 764 (1987).
G. Etemad-Moghadam, D. Delebasse, J.P. Maffrand, and D. Frehel, Syntheses of Na-(ß-naphthyl-sulfonyl-aminoglycyl) argininamides as potential selective synthetic thrombin inhibitors, Eur. J. Med. Chem. 23: 577 (1988).
G. Claeson, S. Gustaysson, and C. Mattsson, New derivatives of p-guanidinophenylalanine as potent reversible inhibitors of thrombin. Thrombos. Haemostas. 50: 53 (Abstr. 0147) (1983).
R. Ferroni, E. Menegatti, and P. Orlandini, Aromatic tetra-amidines: antiproteolytic and antiesterolytic activities towards serine proteinases involved in blood coagulation and clot lysis, Farm. Ed. Sci. 41:464 (1986).
S.W. Oweida, D.N. Ku, A.B. Lamsden, C.M. Kam, and J.C. Powers, In vivo determination of the anticoagulant effect of a substituted isocoumarin (ACITIC),Thromb. Res. 58: 191 (1990).
A. Mor, J. Maillard, C. Favreau, and M. Reboud-Ravauz, Reaction of thrombin and proteinases of the fibrinolytic system with a mechanism-based inhibitor, 3,4-dihydro-3-benzyl-6-chloromethylcoumarin, Biochim. Biophys. Acta 1038: 119 (1990).
M.K. Nishijima, J. Takezawa, N. Taenaka, Y. Shimada, and I. Yoshiya, Application of HPLC measurement of plasma concentration of gabexate esilate, Thromb. Res. 31: 279 (1983).
B. Oedekovan, R. Bey, K. Mottaghy, and H. Schmid-Schönberg, Gabexate mesilate (FOY’) as an anticoagulant in extracorporeal circulation in dogs and sheep, Thrombos. Haemostas. 52: 329 (1984).
H. Olmo, J. Kamnayashi, S.W. Chang, and G. Kosaki, FOY: (Ethyl p-(6guanidinohexanoyloxy)benzoate) methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulo-fibrinolytic system in comparison with heparin or aprotonin, Thromb. Res. 24: 445 (1981).
H. Olmo, G. Kosaki, J. Kambayashi, S. Imaoka, and F. Hirata, FOY:(Ethyl p-(6guanidinohexanoyloxy)benzoate) methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro, Thromb. Res. 19: 579 (1980).
S.V. Pizzo, A.D. Turner, N.A. Porter, and S.L. Gonias, Evaluation of p-amidinophenyl esters as potential antithrombotic agents, Thrombos. Haemostas. 56: 387 (1986).
Y. Hitomi, N. Ikari, and S. Fujii, Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system, Haemostasis 15: 164 (1985).
Y. Koshiyama, A. Kobori, M. Oginara, Y. Yokomoto, K. Ohtari, K. Shimamaura, and M. Iwaki, The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC), Folia Pharmacol, Japan 90: 313 (1987).
T. Yoshikawa, M. Murakami, Y. Furukawa, H. Kato, S. Takemura, and M. Kondo, Effects of FUT-175, a new synthetic protease inhibitor, on endotoxininduced disseminated intravascular coagulation in rats, Haemostasis 13: 374 (1983).
H. Ikoma, K. Ohtsu, Y. Tamao, R. Kikumoto, and S. Okamoto, Effect of a potent thrombin inhibitor, MCI 9038, on novel experimental arterial thrombosis, Blood & Vessel 13: 72 (1982).
S. Nagano, S. Okamoto, K. Ikezawa, K. Mimura, A. Matsuoka, A. Hijikata, and Y. Tamao, Fluorescence studies on the mode of action of two synthetic thrombin inhibitors, No.206 and No.805, Thrombos. Haemostas. 46:(1981) 45 (Abstr. 0128).
K. Oda, K. Ohtsu, R. Tamao, R. Kikumoto, A. Hijikata, K. Kinjo, and S. Okamoto, Comparison of plasma levels and excretory routes between No.189 and No.407, potent thrombin inhibitors, Kobe J. Med. Sci. 26: 11 (1980).
K. Ohtsu, Y. Tamao, R. Kikumoto, K. Ikezawa, A. Hijikata, and S. Okamoto, Effects of a potent thrombin inhibitor No. 407, on DIC models, Kobe J. Med. Sci. 6: 61 (1980).
B. Kaiser, J. Hauptmann, A. Weiß, and F. Markwardt, Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed. Biochim. Acta 44: 1201 (1985).
F. Markwardt, J. Hauptmann, M. Richter, and P. Richter, Tierexexperimentelle untersuchungen zur Pharmakokinetik von 4-Amidinopheny-l-brenztraubensäure (APPA), Pharmazie 34: 178 (1979).
F. Markwardt, A. Hoffmann, and J. Stürzebecher J, Influence of thrombin inhibitors on the thrombin-induced activation of human blood platelets, Haemostasis 13: 227 (1983).
C. Mattsson, E. Eriksson, and s. Nilsson, Anticoagulant and antithrombotic effects of some protease inhibitors, Folia Haematol. (Lpz.) 109: 43 (1982).
B. Kaiser, J. Hauptmann, and F. Marktwardt, Studies on toxicity and pharmacokinetics of the synthetic thrombin inhibitor D-phenylalanyl-L-prolylL-arginine nitrile, Pharmazie 46: 131 (1991).
B. Kaiser, M. Richter, J. Hauptmann, and F. Markwardt, Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolylL-arginine nitrile, Pharmazie 46: 128 (1991).
G.M. Kam, K. Fujikawa, and J.C. Powers, Mechanism-based isocoumarin hibitors for trypsin and blood coagulation serine proteases: New anticoagulants, Biochemistry 27: 2547 (1988).
J. Hauptmann, Degradation of a benzamidine-type synthetic inhibitor of coagulation enzymes in plasma of various species, Thromb. Res. 61: 279 (1991).
W.B. Lawson, V.B. Valenty, J.D. Wos, and A.P. Lobo, Studies on the inhibition of human thrombin: Effects of plasma and plasma constituents, Folia Haematol. (Lpz.) 109: 52 (1992).
D. Green, C-H. Ts’ao, N. Reynolds, D. Kahn, H. Kohl, and I. Cohn, In vitro studies of a new synthetic thrombin inhibitor, Thromb. Res. 37: 145 (1985).
J. Hauptmann, B. Kaiser, and F. Markwardt, Anticoagulant action of synthetic tight binding inhibitors of thrombin in vitro and in vivo, Thromb. Res. 39: 771
M. Niwa, C. Niwa, R. Yamagashi, S. Kondo, K. Takahashi, and N. Sakuragawa, The comparative study on the anticoagulant activities of the synthetic thrombin inhibitor (MD-805) and heparin, Blood & Vessel 16: 421 (1985).
H. Sato, and A. Nakajima, Kinetic study of the initial stage of the fibrinogen-fibrin conversion by thrombin. (III) Effects of competitive inhibitors, Thromb. Res. 37: 327 (1985).
A. Hijikata-Okunomiya, S. Okamoto, and K. Wanaka, Effect of a synthetic thrombin-inhibitor MD 605 on the reaction between thrombin and plasma antithrombin-III, Thromb. Res. 59: 967 (1990).
A.P. Bode, and D.T. Miller, The use of thrombin inhibitors and aprotinin in the preservation of platelets stored for transfusion, J. Lab. Clin. Med. 113: 753 (1989).
E. Glusa, A. Hoffmann, and F. Markwardt, Influence of benzamidine derivatives on thrombin-induced platelet reactions, Folia Haematol. (Lpz.) 109: 86 (1982).
N.J. Greco, T.E. Tenner, and N.N. Tendon, PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification, but does not inhibit platelet shape change, Blood 75: 1983 (1990).
S.R. Hanson, and L.A. Harker, Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-pheny-L-alanyl-L-prolyl-L-arginyl chloromethyl ketone, Proc. Natl. Acad. Sci. USA 85: 3184 (1986).
H. Hara, Y. Tamao, R. Kikumoto, Y. Funahara, A. Hijikata, and S. Okamoto, Effect of a potent thrombin inhibitor, No. 407, on platelet function in vitro and in vivo, Kobe J. Med. Sci. 26: 47 (1980).
I-K. Jang, H.K. Gold, A.A. Ziskind, R.C. Leinbach, J.T. Fallon, and Collen, Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition, Circulation 81: 219 (1990).
F. Markwardt, A. Hoffmann, and J. Stürzebecher, Influence of thrombin inhibitors on the thrombin-induced activation of human blood platelets, Haemostasis 13: 227 (1983).
T. Matsuo, K. Nakao, T. Yamada, and O. Matsuo, Effect of a net anticoagulant (MD 805) on platelet activation in the hemodialysis circuit, Thromb. Res. 41: 33 (1986).
E. Tremoli, P. Maderna, S. Colli, E. Agradi, A. Petroni, and R. Paoletti, GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: activity on platelet aggregation and arachidonic acid metabolism, Pharmacol. Res. Commun. 13: 339 (1981).
E. Pearlstein, C. Ambrogio, G. Gasic, and S. Karpatkin, Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5pentanediyl)-amide, Cancer Res. 41: 4535 (1981).
M. A. Packham, N. L. Bryant, M. A. Guccione, Agglutination of rabbit platelets in plasma by the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone, Thrombos. Haemostas. 63: 282 (1990).
M.W.C. Hatton, and S.L. Moar, Comparative behavior of thrombin and an inactive derivative, FPR-thrombin, toward the rabbit vascular endothelium. Heparin liberates FPR-thrombin from the endothelium in vivo, Circulat. Res. 7: 221 (1990).
N. Gilboa, and J.W. Fenton II, Inhibition of tissue plasminogen activator (TPA) by protein or synthetic thrombin inhibitors, Ann. N. Y. Acad. Sci. 485: 414 (1986).
N. Gilboa, G.B. Villanueva, and J.W. Fenton II, Inhibition of fibrinolytic enzymes by thrombin inhibitors, Enzyme 40: 144 (1988).
M.A. Mohler, C.J. Refino, S.A. Chen, A.B. Chen, and A.J. Hotchkiss, D-PhePro-Arg-chloromethylketone: Its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy, Thrombos. Haemostas. 56: 160 (1986).
E. Seifried, and P. Tanswell, Comparison of specific antibody, D-Phe-Pro-ArgCHZC1 and aprotinin for prevention of in vitro effects of recombinant tissue plasminogen activator on haemostasis parameters. Thrombos. Haemostas. 58: 921 (1987).
Y. Tamao, T. Yamamoto, R. Kikumoto, H. Hara, J. Itoh, T. Hirata, K. Mineo, and S. Okamoto, Effect of a selective thrombin inhibitor MCI-9093 on fibrinolysis in vitro and in vivo, Thrombos. Haemostas. 56: 28 (1986).
J. Hauptmann, B. Kaiser, G. Nowak, J. Stürzebecher, and F. Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors, Thrombos. Haemostas. 63: 220 (1990).
J. Stürzebecher, U. Stürzebecher, H. Vieweg, G. Wagner, J. Hauptmann, and F. Markwardt, Synthetic inhibitors of factor Xa and thrombin. Comparison of their anticoagulant efficiency, Thromb. Res. 54: 242 (1989).
B. Kaiser, J. Hauptmann, and F. Markwardt, Ontersuchungen zur Pharmakodynamik synthetischer Thrombininhibitoren vom Typ basisch substituierter N -arylsulfonylierter Phenylalaninamide, Pharmazie 42: 119 (1987).
S. Okamoto, A. Hijikata, K. Ikezawa, E. Mori, R. Kikumoto, Y. Tamao, K. Ohkubo, T. Texuka, and S. Tonomura, Structure-activity relationship in a series of synthetic thrombin inhibitors: No.205, No.407 and No.700, Blood & Vessel 11: 230 (1980).
C.L. Litterst, Acute and subchronic toxicity of the protease inhibitor Na-tosyl-Llysyl-chloromethylketone (TLCK) in mice, Drug and Chemical Toxicol. 3: 227 (1980).
A. Hijikata-Okunomiya, H. Kitaguchi, and M. Hirata, Effect of MD-805 on plasminogen activator release by thrombin from isolated perfused dog leg, Thromb. Res. 45: 699 (1987).
H-P. Klöcking, A. Hoffmann, and F. Markwardt, Influence of a-NAPAP on thrombin-induced release of plasminogen activator, Thromb. Res. 52: 71 (1968).
M. Mild, K. Ogawa, M. Hirata, H. Kitaguchi, and Y. Funahara, Prostacyclin release from the coronary vascular wall by vasoactive substances, Thromb. Res. 35: 665 (1984).
E. Glusa, and U. Wolfram, The contractile response of vascular smooth muscle to thrombin and its inhibition by thrombin inhibitors, Folia Haematol. (Lpz.) 115: 94 (1988).
D.D. Ku, Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus, J. Pharm. Exp. Ther. 243: 571 (1987).
K. Nakamura, Y. Hatano, and K. Mori, Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor, Thromb. Res. 40: 715 (1985).
M. Melzig, C. Harme, E. Teuscher, B. Voigt, and G. Wagner, Influence of inhibitors of thrombin on porcine aortic smooth muscle cells in primary culture, Biomed. Biochim. Acta 45: 1199 (1986).
L.E. Ostrowski, A. Ahsen, B.P. Suthar, P. Pagast, D.L. Bain, C. Wong, A. Patel, and R.M. Schultz, Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis, Cancer Res. 46: 4121 (1986).
W.K.W. Ho, K. Nakao, and S. Shibata, The inhibitory action of two thrombin inhibitors (TI-189 and TI-233) on the contractile response to 5-hydroxytryptamine and prostaglandin endoperoxide analogue (U-44069) in isolated vascular strips, Brit. J. Pharmacol. 71: 399 (1990).
H. Karaki, K. Murakami, N. Nakagawa, U. Orakawa, The inhibitory effect of N2dansyl-L-arginine-4-t-butylpiperidide amide (TI 233) on contraction of vascular and intestinal smooth muscle, Brit. J. Pharmacol. 80: 519 (1983).
J. Hauptmann, and B. Kaiser, In vitro and in vivo comparison of arginine-and benzamidine-derived highly potent synthetic thrombin inhibitors, Pharmazie 46: 57 (1991).
T. Matsuo, and K. Nakao, Plasma antithrombin activity of MD 805 determined by chromogenic substrate during hemodialysis, Blood and Vessel 18:378 -(1987).
J. Hauptmann, F. Markwardt, and M. Richter, Tierexperimentelle Untersuchungen zur Pharmakokinetik von Na-Tosyl-3-amidino-phenyl-alaninpiperidid (TAPAP), einem neuen Thrombininhibitor, Pharmazie 37: 430 (1962).
F. Markwardt, M. Richter, and G. Vogel, Zur Pharmakokinetik von 4-Amidinophenylbrenztraubensäure, einem neuen synthetischer, Thrombinhemmstoff. Zbl. Pharm. 113: 787 (1974).
M. Paintz, M. Richter, and J. Hauptmann, HPLC-determination of the synthetic thrombin inhibitor Na-(2-naphthylsulfonylglycyl)-4-amidino-phenylalanine piperidide in biological material,Pharmazie 42: 346 (1987).
E. Tremoli, G. Morazzoni, P. Maderna, S. Colli, and R. Paoletti, Studies on the antithrombotic action of BOC-D-Phe-Pro-ArgH (GYKI14,451), Thromb. Res. 23: 549 (1981).
J. Hauptmann, B. Kaiser, M. Paints, and F. Markwardt, Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rats, Biomed. Biochim. Acta 46: 445 (1987).
B. Clement, and M. Zimmermann, Characteristics of the microsomal N-hydroxylation of benzamidine to benzamidoxime, Xenobiotika 17: 659 (1987).
J. Hauptmann, M. Paintz, B. Kaiser, and M. Richter, Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro, Pharmazie 43: 559 (1988).
J. Hauptmann, B. Kaiser, M. Paintz, and F. Markwardt, Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor, Pharmazie 44: 282 (1989).
B. Kaiser, and F. Markwardt, Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors, Thromb. Res. 43: 613 (1986).
J. Hauptmann, B. Kaiser, M. Paintz, and F. Markwardt, Pharmacological characterization of a new structural variant of 4-amidino-phenyl-alanine amide-type synthetic thrombin inhibitor, Pharmazie 44: 282 (1989).
C.N. Vogel, H.S. Kingdon, and R.L. Lundblad, Correlation of in vivo and in vitro inhibition of thrombin by plasma inhibitors, J. Lab. Clin. Med. 93: 661 (1979).
M.A. Shifmann, and S.V, In vivo metabolism of reversibly inhibited-thrombin, Biochem. Pharmacol. 32: 138 (1983).
T. Kumada, and Y. Abiko, Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals, Thromb. Res. 24: 285 (1981).
T. Yamamoto, T. Hirata, M. Inagaki, R. Kikumoto, Y. Tamao and S. Okamoto, Effect of MCI-9038, a selective thrombin inhibitor on cerebral microcirculation after cerebral ischemia in rats, Thrombos. Haemostas. 58: 108 (Abstr. 362) (1967).
R.C. Schaeffer, C. Briston, S-M. Chilton, and R.W. Carlson, Disseminated intravascular coagulation following Echis carinatus venom in dogs: Effects of a synthetic thrombin inhibitor, J. Lab. Clin. Med. 107: 488 (1986).
R.C. Schaeffer, S-M. Chilton, T.J. Hadden, and R.W. Carlson, Pulmonary fibrin microembolism with Echis carinatus venom in dogs: effects of a synthetic thrombin inihibitor, J. Appl. Physiol. 57: 1824 (1984).
A.B. Kelly, S.R. Hanson, L.W. Henderson, and L.A. Harker, Prevention of heparin-resistant thrombotic occlusion of hollow-fiber hemodialyzers by synthetic antithrombin, J. Lab. Clin. Med. 114: 411 (1989).
W.C. Krupski, A. Bass, A.B. Kelly, U.M. Marzec, S.R. Hanson, and L.A. Harker, Heparin-resistant thrombus formation by endovascular stents in baboons. Interruption by a synthetic antithrombin, Circulation 82: 570 (1990).
I.J.K. Jang, H.K. Gold, R.C. Leinbach, J.T. Fallon, and D. Collen, In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator, Circulat. Res. 67: 1552 (1990).
M.J. Mellott, T.M. Conolly, S.J. York, and L.R. Bush, Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA induced thrombolysis in a canine model of femoral arterial thrombosis, Thromb. Haemostas. 64: 526 (1990).
K. Ikezawa, T.Yamashita, S. Okamoto, T. Ohara, K. Takemoto, A. Matsuoka, Improvement of the F VIII:C chromogenic method using the specific synthetic thrombin inhibitors, I-2581 and MD-805, Blood & Vessel 16: 418 (1985).
S. Okamoto, S. Ikezawa, A. Nagano, A. Matsuoka, Y. Hijikata, and Y. Tamao, Selectivity increase of chromogenic assay of factor Xa by use of highly selective synthetic thrombin inhibitor having extremely potent stereostructure (No.605), Thrombos. Haemostas. 46: 313 (Abstr. 0976) (1981).
J. Stürzebecher, and C. Klessen, Einsatz von synthetischen Inhibitoren bei gerinnungsphysiologischen Tests mit Peptidsubstraten, Folia Haematol. (Lpz). 109: 157 (1982).
L. Svendsen, M. Brogli, G. Lindeberg, and K. Stocker K, Differentiation of thrombin-and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitor, Thromb. Res. 34: 457 (1984).
A. Hijikata-Okunomiya, A new method for the determination of prothrombin in human plasma, Thromb. Res. 57: 705 (1990).
M. Hiraishi, Z. Yamasaki, and K. Ichikawa, Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant, Int. J. Artif. Organs 11: 212 (1988).
M.L. Rand, J. Neiman, D.M. Jakowec, and M.A. Packham, Effects of alcohol withdrawal from alcoholics - a study using platelet-rich plasma from blood anticoagulated with D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCHZC1), Thrombos. Haemostas. 63: 178 (1990).
P. Stein, and J. Drawert, Anwendung eines 4-Amidinophenylbrenztraubensäure-Heparin-Stabilisators zur zitratfreien Stabilisierung von Blut, Dtsch. Ges. Wesen. 38: 748 (1983).
T. Matsuo, Y. Chikahira, and Y. Yamada, Effect of synthetic thrombin inhibitor (MD 805) as an alternative drug on heparin-induced thrombocytopenia during hemodialysis, Thromb. Res. 52: 165 (1988).
T. Matsuo, T. Yamada, T. Yamanashi, R. Ryo R, Anticoagulant therapy with MD 805 of a hemodialysis patient with heparin-induced thrombocytopenia, Thromb. Res. 58: 663 (1990).
P.R. Eisenberg, Role of new anticoagulants as adjunctive therapy during thrombolysis, Amer. J. Cardiol. 67: A19 (1991).
H.K. Gold, I.K. Jang, R.C. Leinbach, J.E. McLary, J.T. Fallon, D. Collen, Acceleration of reperfusion by combination of rt-PA and a selective thrombin inhibitor, argatroban, Fibrinolysis Suppl. 3: 15 (Abstr. 40) (1990).
T. Yasuda, H.K. Gold, H. Yaoita, R.C. Leinbach, J.L. Guerrero, I-K. Jang, R. Holt, J.T. Fallon, and D. Collen, Comparative effects of aspirin - synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein Ilb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation, J. Amer. Coll. Cardiol. 16: 714 (1990).
I. Weitz, M. Hudoba, D. Massel, J. Maraganore, and J. Hirsh J, Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors, J. Clin. Invest. 86: 385 (1990).
A.B. Kelly, Y. Cadroy, O.M. Marzec, C.M. Hanson, and L.A. Harker, Comparison of antithrombotic and antihemostatic effects produced by antithrombins in primate models of arterial thrombosis, Thrombos. Haemostas. 62: 42 (Abstr. 93) (1989).
J. Hauptmann, E. Brüggener, and F. Markwardt, Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats, Haemostasis 17: 321 (1987).
C.G. Binnie, B.W. Erickson, and J. Hermans, Inhibition of thrombin by synthetic hirudin peptides, FEBS Lett. 270: 85 (1990).
J.A. Jakubowski, and J.M. Maraganore, Inhibition of coagulation and thrombin induced platelet activities by a synthetic dodecapeptide modeled on the carboxyterminus of hirudin, Blood 75: 399 (1990).
X.J. Yang, M.A. Blajchman, S. Craven, L.M. Smith, N. Anvari, and F.A. Ofosu, Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-CHZC1, Biochem. J. 272: 399 (1990).
J.M. Maraganore, P. Bourdon, J. Jablonski, K.L. Ramachandran, and J.W. Fenton II, Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin, Biochemistry 29: 7095 (1990).
J. Hauptmann, A. Barth, F-P. Schönberger, and F. Markwardt, Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models, Biomed. Biochim. Acta 42: 959 (1983).
B. Kaiser, and F. Markwardt, Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor, Thrombos. Haemostas. 55: 194 (1986).
K. Krupinski, K.N. Breddin, F. Markwardt, and W. Haarmann, Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis, Haemostasis 19: 74 (1989).
J.F. Eidt, P. Allison, S. Noble,J. Ashton, P. Golino, J. McNatt, L.M. Buja, and J.T. Willerson, Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury, J. Clin. Invest. 84: 18 (1989).
H. Hara, Y. Tamao, R. Kikumoto, and S. Okamoto S, Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits, Thrombos. Haemostas. 57: 165 (1987).
T. Yoshikawa, Y. Furukawa, M. Murakami, S. Takemura, and M. Kondo, Protective effect of Gabexate mesilate against experimental disseminated intravascular coagulation in rats, Haemostasis 13: 262 (1983).
G. Vogel, R. Huyke, and I. Heerklotz, Erste klinische Erfahrungen mit dem kleinmolekularen synthetischen Thrombininhibitor 4- amidino-phenylbrenztraubensäure (APPA), Folia Haematol. (Lpz.). 104: 785 (1977).
K. Kumon, K. Tanaka, N. Nakajima, Y. Naito, and T. Fujita, Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation, Critical Care Med. 12: 1039 (1884).
T. Ohshiro, J. Kambayashi, and G. Kosaki, Antithrombotic therapy of patient with peripheral arterial reconstruction - clinical study on MD-805, Blood & Vessel 14: 216 (1983).
K. Yamada, A clinical trial of MD-605, a synthetic thrombin inhibitor. Bibliotheca Haematol. (Basel) 49: 343 (1983).
S. Kobayashi, M. Kitani, S. Yamaguchi, T. Suzuki, K. Okada, and T. Tsunematsu, Effects of an antithrombotic agent (MD-805) or progressing cerebral thrombosis, Thromb. Res. 3: 305 (1969).
N. Taenaka, Y. Shimada, M. Kawai, I. Yoshiya, and G. Kosaki, Survival from DIC following amniotic fluid embolism - successful treatment with a serine proteinase inhibitor - FOY, Anaesthesia 36: 389 (1981).
N. Taenaka, Y. Shimada, T. Hirata, M. Nishijima, and I. Yoshiya, New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY), Crit. Care Med. 10: 773 (1982).
G. Kosaki, J. Kambayashi, and S. Imaoka, Application of a synthetic serine protease inhibitor in the treatment of DIC, Bibliotheca Haematol. (Basel) 49: 317 (1983).
G. Palareti, M. Maccaferri, M. Poggi, F. Petrini, S. Coccheri, F. Haverkate, F. Montanari, and A.S. Corticelli, Effects of gabexate mesilate (FOY), a new synthetic serine protease inhibitor on blood coagulation in patients with DIC, Thrombos. Haemostas. 58: 420 (Abstr. 1544) (1987).
S. Umeki, M. Adachi, and M. Watanabe, Gabexate as a therapy for disseminated intravascular coagulation, Arch. Intern. Med. 148: 1409 (1968).
K. Tanaka, M. Takao, J. Yada, H. Yuasa, M. Kusagawa, and K. Deguchi, Application of gabexate mesilate (FOY) for open heart surgery. Blood & Vessel 19: 612 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Markwardt, F., Hauptmann, J. (1993). Synthetic Thrombin Inhibitors as Anticoagulants Pharmacological Aspects. In: Claeson, G., Scully, M.F., Kakkar, V.V., Deadman, J. (eds) The Design of Synthetic Inhibitors of Thrombin. Advances in Experimental Medicine and Biology, vol 340. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2418-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2418-6_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2420-9
Online ISBN: 978-1-4899-2418-6
eBook Packages: Springer Book Archive